A small number of people report chronic symptoms after receiving COVID-19 shots. A new study provides clues for further research.

Several government resources about accommodations for people with Long COVID have become unavailable in the last week, following purges of government websites and datasets under the Trump administration. These pages offered crucial information about rights under the Americans with Disabilities Act (ADA) for people with Long COVID and their employers.

A PRIMER ON THE NEUROLOGICAL COMPLICATIONS OF SJÖGREN’S DISEASE By Julius Birnbaum, M.D. Johns Hopkins Neurology-Rheumatology Clinic The neurological complications of Sjögren’s disease are extensive and range from cognitive difficulties, […]

People with immune system health problems continue to take precautions against COVID-19 five years into the pandemic.

Numerous host factors, in addition to human angiotensin-converting enzyme 2 (hACE2), have been identified as coreceptors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), demonstrating broad viral tropism and diversified druggable potential. We and others have found that antihistamine …

Scientists and Economists Alert! Global Emergency  Compounded by the AIDS-like Features of SARS-CoV-2 Infection Over a million people in the US are being infected with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) every day.  Originally named after the acute respiratory syndrome it can cause as a consequence of blood vessel damage in the lungs, … Continued

Life-threatening thrombotic events and neurological symptoms are prevalent in COVID-19 and are persistent in patients with long COVID experiencing post-acute sequelae of SARS-CoV-2 infection1,2,3,4. Despite the clinical evidence1,5,6,7, the underlying mechanisms of coagulopathy in COVID-19 and its consequences in inflammation and neuropathology remain poorly understood and treatment options are insufficient. Fibrinogen, the central structural component of blood clots, is abundantly deposited in the lungs and brains of patients with COVID-19, correlates with disease severity and is a predictive biomarker for post-COVID-19 cognitive deficits1,5,8,9,10. Here we show that fibrin binds to the SARS-CoV-2 spike protein, forming proinflammatory blood clots that drive systemic thromboinflammation and neuropathology in COVID-19. Fibrin, acting through its inflammatory domain, is required for oxidative stress and macrophage activation in the lungs, whereas it suppresses natural killer cells, after SARS-CoV-2 infection. Fibrin promotes neuroinflammation and neuronal loss after infection, as well as innate immune activation in the brain and lungs independently of active infection. A monoclonal antibody targeting the inflammatory fibrin domain provides protection from microglial activation and neuronal injury, as well as from thromboinflammation in the lung after infection. Thus, fibrin drives inflammation and neuropathology in SARS-CoV-2 infection, and fibrin-targeting immunotherapy may represent a therapeutic intervention for patients with acute COVID-19 and long COVID.

The pandemic isn’t over. Why is it so hard to find accurate information about it?

Albany Medical Center-led research shows that long Covid patients have the same blood biomarkers, regardless of their symptoms.

A new study finds the risks of developing long COVID declined over the first two years of the pandemic. But unvaccinated adults were more than twice as likely to get long COVID compared with those who were vaccinated.